-
Posted by
Two Blokes Jul 17 -
Filed in
Stock
-
2 views
Nutex Health's financial turnaround is driven by IDR wins, robust revenue growth, and a superior urban microhospital model with industry-leading profitability. Shares are deeply undervalued at 2.1x EV/EBITDA and >30% FCF yield, with significant upside as the market underappreciates Nutex's earnings power and cash flow. Management's heavy insider ownership and consistent share purchases signal long-term commitment and confidence in the business model's sustainability.
